Acadia Pharmaceuticals (ACAD) Return on Capital Employed Growth (3y) (2014 - 2026)
Acadia Pharmaceuticals (ACAD) Return on Capital Employed Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | 4,893.00 |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | -494.00 |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -649.00 |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 4,853.00 |
| 10 | Acadia Pharmaceuticals | 4.36 Bn | 3.51 Bn | 243.27 Mn | 4,765.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,765.00 |
| Dec 31, 2025 | 5,658.00 |
| Sep 30, 2025 | 7,139.00 |
| Jun 30, 2025 | 6,915.00 |
| Mar 31, 2025 | 6,733.00 |
| Dec 31, 2024 | 6,138.00 |
| Sep 30, 2024 | 4,915.00 |
| Jun 30, 2024 | 4,507.00 |
| Mar 31, 2024 | 3,903.00 |
| Dec 31, 2023 | 2,514.00 |
| Sep 30, 2023 | 415.00 |
| Jun 30, 2023 | 763.00 |
| Mar 31, 2023 | -400.00 |
| Dec 31, 2022 | -1,238.00 |
| Sep 30, 2022 | 194.00 |
| Jun 30, 2022 | 2,425.00 |
| Mar 31, 2022 | 2,295.00 |
| Dec 31, 2021 | 4,417.00 |
| Sep 30, 2021 | 7,002.00 |
| Jun 30, 2021 | 4,881.00 |